Growth factors are available for the treatment of short bowel syndrome but have not yet been applied in IBD. The therapeutic application of organoid culture and stem cell therapy to generate new intestinal tissue could provide a novel mechanism to restore barrier function in IBD. Furthermore, ...
(Xiping et al., 2011;Cuiying et al., 2018;Jiajun et al., 2019;Yuxin et al., 2018). However, further in-depth research on SLBZS in the treatment of UC is needed like the molecular and cellular mechanism of actions, more exhaustive pharmacological studies to substantiate the ef...
Perturbations in the intestinal microbiome are strongly linked to the pathogenesis of inflammatory bowel disease (IBD). Bacteria, fungi and viruses all make up part of a complex multi-kingdom community colonizing the gastrointestinal tract, often referred to as the gut microbiome. They can exert var...
The mechanism involves the competition of the PPI and clopidogrel with the same cytochrome P450 (CYP2C19). Whether this is a class effect of PPIs is unclear; there appears to be at least a theoretical advantage of pantoprazole over the other PPIs, but this has not been confirmed. This drug ...
15 July2016 Sara Al-Ghadban1, Samira Kaissi1, Fadia R. Homaidan2, Hassan Y. Naim3 & Marwan E. El-Sabban1 Inflammatory bowel disease (IBD) involves functional impairment of intestinal epithelial cells (IECs), concomitant with the infiltration of the lamina propria by infla...
Inflammatory bowel disease (IBD) specifically refers to two idiopathic chronic inflammatory diseases involving the gut: ulcerative colitis (UC) and Crohn’s disease (CD). UC and CD share some clinical and pathological features, and distinction between th
The major research challenge both for PSC and IBD is to unravel the underlying pathophysiological mechanism. Ultimately this will be essential for development of targeted drug therapy. In PSC, patients should ideally be identified in a very early disease stage, before irreversible bile duct fibrosis ...
Although the treatment of IBD with biological molecules, specifically with monoclonal antibodies, presents high specificity and directed mechanism of action, the high cost of this therapy still represents a barrier to be overcome. For this reason, together with this being a therapy in early stages ...
Inflammatory bowel disease (IBD) is a complex genetic disease that is instigated and amplified by the confluence of multiple genetic and environmental variables that perturb the immune–microbiome axis. The challenge of dissecting pathological mechanisms underlying IBD has led to the development of transf...
Which and how are lncRNAs and circRNAs involved in the internal mechanism of IBD? Will lncRNAs and circRNAs serve as clinical biomarkers of IBD? Introduction Inflammatory bowel disease (IBD) is a chronic inflammatory disease within the gastrointestinal tract. The two major subtypes of IBD are ulcera...